Avalo Therapeutics Inc
C6K0
Company Profile
Business description
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
Contact
1500 Liberty Ridge Drive
Suite 321
WaynePA19087
USAT: +1 410 522-8707
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
33
Stocks News & Analysis
stocks
ASX iron ore player downgraded ahead of earnings
Rising costs and delayed production drive fair value cut for ASX iron ore player.
stocks
Global tensions drive profitability for ASX energy provider
Supply disruptions turbocharge refining profits and lift earnings forecasts for ASX energy share.
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,405.40 | 59.70 | 0.64% |
| CAC 40 | 8,674.14 | 7.51 | 0.09% |
| DAX 40 | 26,267.03 | 64.68 | 0.25% |
| Dow JONES (US) | 54,085.88 | 907.47 | 1.71% |
| FTSE 100 | 10,898.99 | 19.61 | 0.18% |
| HKSE | 25,915.82 | 62.90 | 0.24% |
| NASDAQ | 26,584.99 | 671.10 | 2.59% |
| Nikkei 225 | 66,300.44 | 2,342.91 | 3.66% |
| NZX 50 Index | 13,997.18 | 93.72 | 0.67% |
| S&P 500 | 7,736.52 | 136.02 | 1.79% |
| S&P/ASX 200 | 9,227.80 | 51.30 | 0.56% |
| SSE Composite Index | 3,878.43 | 56.15 | 1.47% |